

**Piperacillin
Tazobactam**

TAZOCIN[®]

2 g/250 mg; 4 g/500 mg

Lyophilized Powder for I.V. Injection




1. PHARMACOLOGIC CATEGORY

Antibacterial


2. DESCRIPTION

Piperacillin/tazobactam is an injectable antibacterial combination consisting of the semisynthetic antibiotic piperacillin sodium and the β -lactamase inhibitor tazobactam sodium for intravenous administration.

Piperacillin sodium is derived from D(-)- α -aminobenzylpenicillin. The chemical name of piperacillin sodium is sodium (2S, 5R, 6R)-6-[(R)-2-(4-ethyl-2,3-dioxo-1-piperazinecarboxamido)-2-phenylacetamido] -3,3 - dimethyl-7-oxo-4-thia-1-azabicyclo [3.2.0]heptane - 2 - carboxylate. Piperacillin sodium is a white, crystalline powder. It is freely soluble in water, alcohol, and methyl alcohol but is practically insoluble in ethyl acetate. Its structural formula is:



Tazobactam sodium is a derivative of the penicillin nucleus. Chemically, tazobactam is a penicillanic acid sulfone. Its chemical name is sodium(2S-,3S-,5R) - 3 - methyl-7-oxo-3-(1H-1,2,3-triazol-1-ylmethyl)-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate,4,4-dioxide. Tazobactam sodium is a white to pale yellow non-hydroscopic crystalline powder. The chemical structure of tazobactam sodium is:



3. FORMULATION/COMPOSITION

2.25 g vial: Each single-dose vial contains piperacillin sodium equivalent to 2 g of piperacillin and tazobactam sodium equivalent to 0.25 g of tazobactam. It also contains 72 mg citric acid

monohydrate (as the free anhydrous acid) and 0.5 mg of edetate disodium (dihydrate) (EDTA) per vial.

4.5 g vial: Each single-dose vial contains piperacillin sodium equivalent to 4 g of piperacillin and tazobactam sodium equivalent to 0.5 g of tazobactam. It also contains 144 mg citric acid monohydrate (as the free anhydrous acid) and 1 mg of edetate disodium (dihydrate) (EDTA) per vial.

4. CLINICAL PARTICULARS

4.1. Therapeutic Indications

Piperacillin/tazobactam (Tazocin) is indicated for the treatment of the following systemic and/or local bacterial infections caused by gram-positive and gram-negative aerobic and anaerobic organisms susceptible to piperacillin/tazobactam or piperacillin:

Adults

- Lower respiratory tract infections
- Urinary tract infections
- Intra-abdominal infections
- Skin and skin structure infections
- Bacterial septicemia
- Gynecological infections, including post-partum endometritis and pelvic inflammatory disease (PID)
- Febrile neutropenic infections. Combination treatment with an aminoglycoside is recommended.
- Bone and joint infections
- Polymicrobial infections (gram-positive/gram-negative aerobes and anaerobes)

Children (2 years of age or older)

- Febrile neutropenic infections. Combination treatment with an aminoglycoside is recommended
- Intra-abdominal infections

In serious infections, empiric therapy with piperacillin/tazobactam may be initiated before susceptibility test results are available.

Note: For associated bacteremia due to extended-beta-lactamase (ESBL) producing organisms, see **section 5.1 Pharmacodynamic Properties**.

4.2. Dosage and Method of Administration

Piperacillin/tazobactam (Tazocin) must be given by slow intravenous infusion (e.g., over 20-30 minutes).

• Duration of Therapy

The duration of therapy should be guided by the severity of the infection and the patient's clinical and bacteriological progress.

- **Adults and Children Aged 12 Years and Older**

In general, the recommended total daily dosage is 12 g of piperacillin/1.5 g of tazobactam given in divided doses every 6 or 8 hours. Doses as high as 18 g of piperacillin/2.25 g of tazobactam per day in divided doses can be used in severe infections.

Pediatric Neutropenia

Febrile neutropenic patients in combination with an aminoglycoside:

For children with normal renal function and weighing less than 50 kg, the dose should be adjusted to 80 mg of piperacillin/10 mg of tazobactam per kilogram of body weight every 6 hours, in combination with the appropriate dose of an aminoglycoside.

For children weighing over 50 kg, follow the adult dosing, in combination with the appropriate dose of an aminoglycoside.

Pediatric Intra-Abdominal Infection

For children aged 2 to 12 years, weighing up to 40 kg, and with normal renal function, the recommended dose is 100 mg piperacillin/12.5 mg tazobactam per kilogram of body weight every 8 hours.

For children aged 2 to 12 years, weighing over 40 kg, and with normal renal function, follow the adult dosing guidance. Therapy is recommended for a minimum of 5 days and a maximum of 14 days, considering that dose administration should continue at least 48 hours after the resolution of clinical signs and symptoms.

- **Use in Patients with Renal Impairment**

In patients with renal impairment or in hemodialysis patients, intravenous dosages and administration intervals should be adjusted to the degree of renal function impairment as follows.

Creatinine Clearance (mL/min)	Piperacillin/Tazobactam (recommended dose)
>40	No dose adjustment necessary
20-40	Maximum dose suggested: 4 g/0.5 g every 8 hours
<20	Maximum dose suggested: 4 g/0.5 g every 12 hours

For patients on hemodialysis, one additional dose of piperacillin/tazobactam 2 g/0.25 g should be administered following each dialysis period, because hemodialysis removes 30%-50% of piperacillin in 4 hours.

- **Use in Patients with Hepatic Impairment**

No dosage adjustment is necessary in patients with hepatic impairment.

- **Co-administration of Piperacillin/Tazobactam with Aminoglycosides**

Due to the *in vitro* inactivation of the aminoglycoside by β -lactam antibiotics, piperacillin/tazobactam and the aminoglycoside are recommended for separate administration. Piperacillin/tazobactam and the aminoglycoside should be reconstituted and diluted separately when concomitant therapy with aminoglycosides is indicated (see **section 6.4 Incompatibilities**).

In circumstances where co-administration is preferred, piperacillin/tazobactam containing EDTA supplied in vials is compatible for simultaneous co-administration via Y-site infusion only with the following aminoglycosides under the following conditions:

Aminoglycoside	Piperacillin/Tazobactam dose (g)	Piperacillin/Tazobactam Diluent Volume (mL)	Aminoglycoside Concentration Range[‡] (mg/mL)	Acceptable Diluents
Amikacin	2.25	50	1.75–7.5	0.9% sodium chloride or 5% dextrose
	4.5	150		
Gentamicin	2.25	50	0.7–3.32	0.9% sodium chloride or 5% dextrose
	4.5	150		

[‡] The dose of aminoglycoside should be based on patient weight, status of infection (serious or life-threatening) and renal function (creatinine clearance).

Compatibility of piperacillin/tazobactam with other aminoglycosides has not been established. Only the concentration and diluents for amikacin and gentamicin with the dosages of piperacillin/tazobactam listed in the table above have been established as compatible for co-administration via Y-site infusion. Simultaneous co-administration via Y-site infusion in any manner other than listed above may result in inactivation of the aminoglycoside by piperacillin/tazobactam.

- **Geriatric Population**

Patients over 65 years are not at an increased risk of developing adverse effects solely because of age. However, dosage should be adjusted in the presence of renal insufficiency.

4.3. Contraindications

Hypersensitivity to any of the β -lactams (including penicillins and cephalosporins) or to β -lactamase inhibitors.

4.4. Special Warnings and Precautions for Use

Before initiating therapy with piperacillin/tazobactam, careful inquiry should be made concerning previous hypersensitivity reactions to penicillins, cephalosporins, and other allergens. Serious and occasionally fatal hypersensitivity (anaphylactic/anaphylactoid [including shock]) reactions have been reported in patients receiving therapy with penicillins including piperacillin/tazobactam. These reactions are more likely to occur in persons with a history of sensitivity to multiple allergens. Serious hypersensitivity reactions require discontinuation of the antibiotic, and may require administration of epinephrine and other emergency measures.

Piperacillin/tazobactam may cause severe cutaneous adverse reactions, such as Stevens-Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, and acute generalized exanthematous pustulosis (see **section 4.8 Undesirable Effects**). If patients develop a skin rash they should be monitored closely and piperacillin/tazobactam discontinued if lesions progress.

Antibiotic-induced pseudomembranous colitis may manifest as severe persistent diarrhea which may be life-threatening. The onset of pseudomembranous colitis symptoms may occur during or after antibacterial treatment.

Bleeding manifestations have occurred in some patients receiving β -lactam antibiotics. These reactions sometimes have been associated with abnormalities of coagulation tests such as clotting time, platelet aggregation and prothrombin time, and are more likely to occur in patients with renal failure (see **section 4.5 Interaction with Other Medicinal Products and Other Forms of Interaction**). If bleeding manifestations occur, the antibiotic should be discontinued and appropriate therapy instituted.

This product contains 2.84 mEq (65 mg) of sodium per gram of piperacillin which may increase a patient's overall sodium intake. Hypokalemia may occur in patients with low potassium reserves or in those who are receiving concomitant medications that may lower potassium levels; periodic electrolyte determinations may be advisable in such patients.

Leukopenia and neutropenia may occur, especially during prolonged therapy. Therefore, periodic assessment of hematopoietic function should be performed.

As with treatment with other penicillins, neurological complications in the form of convulsions (seizures) may occur when high doses are administered, especially in patients with impaired renal function (see **section 4.8 Undesirable Effects**).

As with other antibiotic preparations, use of this drug may result in overgrowth of non-susceptible organisms, including fungi. Patients should be carefully monitored during therapy. If superinfection occurs, appropriate measures should be taken.

- **Use in Patients with Hepatic Impairment**

(see **section 4.2 Dosage and Method of Administration**).

- **Renal Impairment**

Due to its potential nephrotoxicity (see **section 4.8 Undesirable Effects**), piperacillin/tazobactam should be used with care in patients with renal impairment or in hemodialysis patients. Intravenous dosages and administration intervals should be adjusted to the degree of renal function impairment (see **section 4.2 Dosage and Method of Administration, Use in Patients with Renal Impairment** for dosage adjustments).

In a secondary analysis using data from a large multicenter, randomized-controlled trial when glomerular filtration rate (GFR) was examined after administration of frequently used antibiotics in critically ill patients, the use of piperacillin/tazobactam was associated with a lower rate of reversible GFR improvement compared with the other antibiotics. This secondary analysis concluded that piperacillin/tazobactam was a cause of delayed renal recovery in these patients.

Combined use of piperacillin/tazobactam and vancomycin may be associated with an increased incidence of acute kidney injury (see **section 4.5 Interaction with Other Medicinal Products and Other Forms of Interaction**).

4.5. Interaction with Other Medicinal Products and Other Forms of Interaction

- **Non-Depolarizing Muscle Relaxants**

Piperacillin, when used concomitantly with vecuronium, has been implicated in prolonging the neuromuscular blockade of vecuronium. Due to their similar mechanism of action, it is expected that the neuromuscular blockade produced by any of the non-depolarizing muscle relaxants could be prolonged in the presence of piperacillin.

- **Anticoagulants**

During simultaneous administration of heparin, oral anticoagulants and other drugs that may affect the blood coagulation system, including thrombocyte function, appropriate coagulation tests should be performed more frequently and monitored regularly (see **section 4.4 Special Warnings and Precautions for Use**).

- **Methotrexate**

Piperacillin may reduce the excretion of methotrexate; therefore, serum levels of methotrexate should be monitored in patients to avoid drug toxicity.

- **Probenecid**

As with other penicillins, concurrent administration of probenecid and piperacillin/tazobactam produces a longer half-life and lower renal clearance for both piperacillin and tazobactam; however, peak plasma concentrations of either drug are unaffected.

- **Aminoglycosides**

Piperacillin, either alone or with tazobactam, did not significantly alter the pharmacokinetics of tobramycin in subjects with normal renal function and with mild or moderate renal impairment. The pharmacokinetics of piperacillin, tazobactam, and the M1 metabolite were also not significantly altered by tobramycin administration.

- **Vancomycin**

Studies have detected an increased incidence of acute kidney injury in patients concomitantly administered piperacillin/tazobactam and vancomycin as compared to vancomycin alone (see **section 4.4 Special Warnings and Precautions for Use**). Some of these studies have reported that the interaction is vancomycin dose-dependent. Expert guidelines recommend intensive vancomycin dosing and maintenance of trough levels between 15 mg/L and 20 mg/L which is an increase from previously published recommendations of target trough concentrations of 5-10 mg/L. Attaining these trough concentrations often requires practitioners to prescribe vancomycin doses which exceed manufacturers' recommendations. Therefore, it is possible that in addition to the increased risk of vancomycin-induced nephrotoxicity reported with adherence to these guidelines the risk of nephrotoxicity may also increase due to an interaction with piperacillin/tazobactam.

No pharmacokinetic interactions have been noted between piperacillin/tazobactam and vancomycin.

As with other penicillins, the administration of piperacillin/tazobactam may result in a false-positive reaction for glucose in urine using a copper-reduction method. It is thus recommended that glucose tests based on enzymatic glucose oxidase reactions be used.

There have been reports of positive test results using the Bio-Rad Laboratories Platelia *Aspergillus* enzyme immunoassay (EIA) test in patients receiving piperacillin/tazobactam injection who were subsequently found to be free of *Aspergillus* infection. Cross-reactions with non-*Aspergillus* polysaccharides and polyfuranoses with Bio-Rad Laboratories Platelia *Aspergillus* EIA test have been reported.

Therefore, positive test results in patients receiving piperacillin/tazobactam should be interpreted cautiously and confirmed by other diagnostic methods.

4.6. Fertility, Pregnancy and Lactation

Studies in animals have not shown teratogenicity with piperacillin/tazobactam combination when administered intravenously but have shown reproductive toxicity in rats at maternally toxic doses when administered intravenously or intraperitoneally. There are no adequate and well-controlled studies with the piperacillin/tazobactam combination or with piperacillin or tazobactam alone in pregnant women. Piperacillin and tazobactam cross the placenta. Pregnant women should be treated only if the expected benefit outweighs the possible risks to the pregnant woman and the fetus.

Piperacillin is excreted in low concentrations in human milk; tazobactam concentrations in human milk have not been studied. Women who are breast-feeding should be treated only if the expected benefit outweighs the possible risks to the woman and child.

4.7. Effects on Ability to Drive and Use Machines

No studies on the effect of ability to drive or use machines have been performed.

4.8. Undesirable Effects

Table 1. Adverse Drug Reactions

System Organ Class	Adverse Drug Reactions
Infections and infestations	pseudomembranous colitis, candida infection*
Blood and lymphatic system disorders	pancytopenia*, agranulocytosis, neutropenia, hemolytic anemia*, thrombocytopenia, anemia*, leukopenia, thrombocytosis*, eosinophilia*
Immune system disorders	anaphylactoid shock*, anaphylactic shock*, anaphylactoid reaction*, anaphylactic reaction*, hypersensitivity*
Metabolism and nutrition disorders	hypokalemia
Psychiatric disorders	delirium*, insomnia
Nervous system disorders	seizure*, headache
Vascular disorders	hypotension, phlebitis, thrombophlebitis, flushing
Respiratory, thoracic and mediastinal disorders	eosinophilic pneumonia*, epistaxis
Gastrointestinal disorders	stomatitis, abdominal pain, vomiting, diarrhea, constipation, nausea, dyspepsia
Hepatobiliary disorders	hepatitis*, jaundice
Skin and subcutaneous tissue disorders	toxic epidermal necrolysis*, Stevens-Johnson syndrome*, drug reaction with eosinophilia and systemic symptoms (DRESS)*, acute generalized exanthematous pustulosis (AGEP)*, dermatitis exfoliative*, erythema multiforme*, dermatitis bullous, rash, pruritus, urticaria, rash maculo-papular*, purpura
Musculoskeletal and connective tissue disorders	arthralgia, myalgia
Renal and urinary disorders	renal failure, tubulointerstitial nephritis*
General disorders and administration site conditions	pyrexia, injection site reaction, chills
Investigations	Coombs direct test positive, activated partial thromboplastin time prolonged, prothrombin time prolonged, bleeding time prolonged, blood albumin decreased, protein total decreased, blood glucose decreased, aspartate aminotransferase increased, alanine aminotransferase increased, blood alkaline phosphatase increased, blood bilirubin increased, gamma-glutamyl transferase increased, blood creatinine increased, blood urea increased

*Adverse Drug Reaction (ADR) identified post-marketing

Piperacillin therapy has been associated with an increased incidence of fever and rash in cystic fibrosis patients.

4.9. Overdose and Treatment

- **Symptoms**

There have been post-marketing reports of overdose with piperacillin/tazobactam. The majority of the adverse events experienced including nausea, vomiting, and diarrhea have also been reported with the usual recommended dosages. Patients may experience neuromuscular excitability or convulsions if higher than recommended doses are given intravenously (particularly in the presence of renal failure).

- **Treatment**

Treatment should be supportive and symptomatic according to the patient's clinical presentation.

No specific antidote is known. Excessive serum concentrations of either piperacillin or tazobactam may be reduced by hemodialysis (see **section 5.2 Pharmacokinetic Properties**).

5. PHARMACOLOGICAL PROPERTIES

5.1. Pharmacodynamic Properties

Pharmacotherapeutic Group:

Antibacterials for systemic use, combinations of penicillins including β -lactamase inhibitors; ATC code: J01C R05.

Mechanism of Action

Sterile piperacillin sodium/tazobactam sodium (Tazocin) is an injectable antibacterial combination consisting of the semisynthetic antibiotic piperacillin sodium and the β -lactamase inhibitor tazobactam sodium for intravenous administration. Thus, piperacillin/tazobactam combines the properties of a broad-spectrum antibiotic and a β -lactamase inhibitor.

Piperacillin sodium exerts bactericidal activity by inhibiting septum formation and cell wall synthesis. Piperacillin and other β -lactam antibiotics block the terminal transpeptidation step of cell wall peptidoglycan biosynthesis in susceptible bacteria by interacting with penicillin-binding proteins (PBPs), the bacterial enzymes that carry out this reaction. *In vitro*, piperacillin is active against a variety of gram-positive and gram-negative aerobic and anaerobic bacteria.

Piperacillin has reduced activity against bacteria harboring certain β -lactamase enzymes, which chemically inactivate piperacillin and other β -lactam antibiotics. Tazobactam sodium, which has very little intrinsic antimicrobial activity, due to its low affinity for PBPs, can restore or enhance the activity of piperacillin against many of these resistant organisms. Tazobactam is a potent inhibitor of many class A β -lactamases (penicillinases, cephalosporinases and extended spectrum enzymes). It has variable activity against class A carbapenemases and class D β -lactamases. It is not active against most class C cephalosporinases and inactive against class B metallo- β -lactamases.

Two features of piperacillin/tazobactam lead to increased activity against some organisms harboring β -

lactamases that, when tested as enzyme preparations, are less inhibited by tazobactam and other inhibitors: tazobactam does not induce chromosomally mediated β -lactamases at tazobactam levels achieved with the recommended dosing regimen and piperacillin is relatively refractory to the action of some β -lactamases.

Like other β -lactam antibiotics, piperacillin, with or without tazobactam, demonstrates time-dependent bactericidal activity against susceptible organisms.

Mechanism of Resistance

There are three major mechanisms of resistance to β -lactam antibiotics: changes in the target PBPs resulting in reduced affinity for the antibiotics, destruction of the antibiotics by bacterial β -lactamases, and low intracellular antibiotic levels due to reduced uptake or active efflux of the antibiotics.

In gram-positive bacteria, changes in PBPs are a major mechanism of resistance to β -lactam antibiotics, including piperacillin/tazobactam. This mechanism is responsible for methicillin resistance in staphylococci and penicillin resistance in *Streptococcus pneumoniae* as well as viridans group streptococci and enterococci. Resistance caused by changes in PBPs also occurs to a lesser extent in fastidious gram-negative species such as *Haemophilus influenzae* and *Neisseria gonorrhoeae*. Piperacillin/tazobactam is not active against strains in which resistance to β -lactam antibiotics is determined by altered PBPs. As indicated above, there are some β -lactamases that are not inhibited by tazobactam.

MERINO Trial (blood stream infections due to ESBL producing organisms)

In a prospective, randomized non-inferiority clinical trial, definitive (i.e., based on susceptibility confirmed *in-vitro*) treatment with piperacillin/tazobactam did not meet non-inferiority in regard to 30-day mortality in the treatment of blood stream infections due to ESBL producing *E. coli* or *Klebsiella pneumoniae* in critically ill adult patients. A total of 23 of 187 patients (12.3%) randomized to piperacillin/tazobactam met the primary outcome of mortality at 30 days compared with 7 of 191 (3.7%) randomized to meropenem (risk difference, 8.6% [1-sided 97.5% CI – ∞ to 14.5%]; $P = 0.90$ for non-inferiority). Clinical and microbiological resolution by day 4 occurred in 121 of 177 patients (68.4%) in the piperacillin/tazobactam group compared with 138 of 185 (74.6%), randomized to meropenem (risk difference, –6.2% [95% CI, –15.5 to 3.1%]; $P = 0.19$). The cause of the mortality imbalance is not clear. This study was not sponsored by Pfizer.

Methodology for Determining the *In Vitro* Susceptibility of Bacteria to Piperacillin/Tazobactam

Susceptibility testing should be conducted using standardized laboratory methods, such as those described by the Clinical and Laboratory Standards Institute (CLSI). These include dilution methods (minimal inhibitory concentration [MIC] determination) and disk susceptibility methods. Both CLSI and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) provide susceptibility interpretive criteria for some bacterial species based on these methods. It should be noted that for the disk diffusion method, CLSI and EUCAST use disks with different drug contents of piperacillin and tazobactam.

CLSI Reference Information (for markets referencing the CLSI)

The CLSI interpretive criteria for susceptibility testing of piperacillin/tazobactam are listed in the following table:

CLSI Susceptibility Interpretive Criteria for Piperacillin/Tazobactam						
Pathogen	Minimal Inhibitory Concentration (mg/L of Piperacillin)^a			Disk^b Diffusion Inhibition Zone (mm Diameter)		
	S	I	R	S	I	R
<i>Enterobacteriaceae</i>	≤16	32-64	≥128	≥21	18-20	≤17
<i>Acinetobacter</i> spp.	≤16	32-64	≥128	≥21	18-20	≤17
<i>Pseudomonas aeruginosa</i>	≤16	32-64	≥128	≥21	15-20	≤14
Certain other non-fastidious gram-negative bacilli ^c	-	-	-	≥21	18-20	≤17
<i>Haemophilus influenzae</i> and <i>Haemophilus parainfluenzae</i>	≤1	-	≥2	≥21	-	-
Anaerobes ^d	≤32	64	≥128	-	-	-
Source: Clinical and Laboratory Standards Institute. <i>Performance Standards for Antimicrobial Susceptibility Testing</i> ; CLSI document M100;ED29. CLSI, Wayne, PA, 2019. This document is updated annually and may be accessed at http://clsi-m100.com/ . S = Susceptible. I = Intermediate. R = Resistant. ^a MICs are determined using a fixed concentration of 4 mg/L tazobactam and by varying the concentration of piperacillin. ^b CLSI interpretive criteria are based on disks containing 100 µg of piperacillin and 10 µg of tazobactam. ^c Refer to CLSI Document M100 Table 2B-5 for the list of organisms included. ^d With the exception of <i>Bacteroides fragilis</i> , MICs are determined by agar dilution only.						

Standardized susceptibility test procedures require the use of quality control microorganisms to control the technical aspects of the test procedures. Quality control microorganisms are specific strains with intrinsic biological properties relating to resistance mechanisms and their genetic expression within the microorganism; the specific strains used for susceptibility test quality control are not clinically significant.

Organisms and quality control ranges for piperacillin/tazobactam to be utilized with CLSI methodology and susceptibility test interpretive criteria are listed in the following table:

QUALITY CONTROL RANGES FOR PIPERACILLIN/TAZOBACTAM TO BE USED IN CONJUNCTION WITH CLSI SUSCEPTIBILITY TEST INTERPRETIVE CRITERIA		
	Minimal Inhibitory Concentration (mg/L of piperacillin)	Disk Diffusion Inhibition Zone (mm Diameter)
Quality Control Strain		
<i>Escherichia coli</i> ATCC 25922	1–4	24–30
<i>Escherichia coli</i> ATCC 35218	0.5–2	24–30
<i>Pseudomonas aeruginosa</i> ATCC 27853	1–8	25–33
<i>Haemophilus influenzae</i> ATCC 49247	0.06–0.5	33–38
<i>Staphylococcus aureus</i> ATCC 29213	0.25–2	-
<i>Staphylococcus aureus</i> ATCC 25923	-	27–36
<i>Bacteroides fragilis</i> ATCC 25285	0.12–0.5 ^a	-
<i>Enterococcus faecalis</i> ATCC 29212	1–4	
<i>Bacteroides thetaiotaomicron</i> ATCC 29741	4–16 ^a	-
<i>Clostridiodes</i> (formerly <i>Clostridium</i>) <i>difficile</i> ATCC 700057	4–16 ^a	
<i>Eggerthella lenta</i> (formerly <i>Eubacterium lentum</i>) ATCC 43055	4–16 ^a	
Source: Clinical and Laboratory Standards Institute. <i>Performance Standards for Antimicrobial Susceptibility Testing</i> , CLSI document M100 ED29. CLSI, Wayne, PA, 2019.		
^a Agar dilution only.		

EUCAST Reference Information (for markets referencing the EUCAST)

EUCAST has also established clinical breakpoints for piperacillin/tazobactam against some organisms. Like CLSI, the EUCAST MIC susceptibility criteria are based on a fixed concentration of 4 mg/L of tazobactam. However, for inhibition zone determination, the disks contain 30 µg of piperacillin and 6 µg of tazobactam. The EUCAST rationale document for piperacillin/tazobactam (Piperacillin-tazobactam. Rationale for the EUCAST clinical breakpoints, version 1.0. 22nd November 2010). states that breakpoints for *Pseudomonas aeruginosa* apply to dosages of 4 g, 4 times daily, whereas the breakpoints for other organisms are based on 4 g, 3 times daily.

The EUCAST breakpoints for piperacillin/tazobactam are listed in the following table:

EUCAST Susceptibility Interpretive Criteria for Piperacillin/tazobactam				
	Minimal Inhibitory Concentration (mg/L of Piperacillin) ^a		Disk ^b Diffusion Inhibition Zone (mm Diameter)	
Pathogen	S	R	S	R
<i>Enterobacteriales</i> (formerly <i>Enterobacteriaceae</i>)	≤8	>16	≥20	<17
<i>Pseudomonas aeruginosa</i>	≤16	>16	≥18	<18
<i>Haemophilus influenzae</i>	≤0.25	≤0.25	≥27	<27
Gram-positive anaerobes	≤8	>16	-	-

Gram-negative anaerobes	≤8	>16	-	-
Non-species related (PK-PD)	≤4	>16	-	-
Sources: EUCAST Clinical Breakpoint Table v. 9.0, 1 January, 2019. S = Susceptible. R = Resistant. ^a MICs are determined using a fixed concentration of 4 mg/L tazobactam and by varying the concentration of piperacillin. ^b EUCAST interpretive criteria are based on disks containing 30 µg of piperacillin and 6-µg of tazobactam.				

Per EUCAST, for species without piperacillin/tazobactam breakpoints, susceptibility in staphylococci is inferred from cefoxitin/oxacillin susceptibility. For groups A, B, C and G streptococci and *Streptococcus pneumoniae*, susceptibility is inferred from benzylpenicillin susceptibility. For other streptococci, enterococci, and β -lactamase-negative *Haemophilus influenzae*, susceptibility is inferred from amoxicillin-clavulanate susceptibility. There are no EUCAST breakpoints for *Acinetobacter*. The EUCAST rationale document for piperacillin/tazobactam states that in endocarditis caused by streptococci other than groups A, B, C and G and *S. pneumoniae*, national or international guidelines should be referred to.

Quality control ranges for EUCAST susceptibility breakpoints are listed in the following table.

Quality Control Ranges for Piperacillin/Tazobactam to be Used in Conjunction with EUCAST Susceptibility Test Interpretive Criteria		
Quality Control Strain	Minimal Inhibitory Concentration (mg/L of piperacillin)	Disk Diffusion Inhibition Zone (mm Diameter)
<i>Escherichia coli</i> ATCC 25922	1-4	21-27
<i>Escherichia coli</i> ATCC 35218	0.5-2	21-27
<i>Pseudomonas aeruginosa</i> ATCC 27853	1-8	23-29
<i>Klebsiella pneumoniae</i> ATCC 700603	8-32	14-20
Source: The European Committee on Antimicrobial Susceptibility Testing. Routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST. Version 9.0, 2019. http://www.eucast.org .		

Antibacterial Spectrum (Groupings of relevant species according to piperacillin / tazobactam susceptibility)

Commonly Susceptible Species

Aerobic gram-positive microorganisms:

Enterococcus faecalis (ampicillin-or penicillin-susceptible isolates only)

Listeria monocytogenes

Staphylococcus aureus (methicillin-susceptible isolates only)

Staphylococcus spp., coagulase-negative (methicillin-susceptible isolates only)

Streptococcus agalactiae (Group B streptococci)[†]

Streptococcus pyogenes (Group A streptococci)[†]

Aerobic gram-negative microorganisms:

Citrobacter koseri

Haemophilus influenzae

Moraxella catarrhalis

Proteus mirabilis

Anaerobic gram-positive microorganisms:

Clostridium spp.

Eubacterium spp.

Anaerobic gram-positive cocci^{††}

Anaerobic gram-negative microorganisms:

Bacteroides fragilis group

Fusobacterium spp.

Porphyromonas spp.

Prevotella spp.

Species for which acquired resistance may be a problem

Aerobic gram-positive microorganisms:

Enterococcus faecium

Streptococcus pneumoniae^{††}

Viridans group streptococci^{††}

Aerobic gram-negative microorganisms:

Acinetobacter baumannii

Citrobacter freundii

Enterobacter spp.

Escherichia coli

Klebsiella pneumoniae

Morganella morganii

Proteus vulgaris

Providencia spp.

Pseudomonas aeruginosa

Serratia spp.

Anaerobic gram-positive microorganisms:

Clostridium perfringens

Anaerobic gram-negative microorganisms:

Bacteroides distasonis

Prevotella melaninogenica

Inherently resistant organisms

Aerobic gram-positive microorganisms

Corynebacterium jeikeium

Aerobic gram-negative microorganisms

Burkholderia cepacia

Legionella spp.

Stenotrophomonas maltophilia

Other microorganisms

Chlamydophila pneumoniae

Mycoplasma pneumoniae

† Streptococci are not β -lactamase producing bacteria; resistance in these organisms is due to alterations in penicillin-binding proteins (PBPs) and, therefore, piperacillin/tazobactam-susceptible isolates are susceptible to piperacillin alone. Penicillin resistance has not been reported in *S. pyogenes*.

†† Including *Anaerococcus*, *Finnegoldia*, *Peptococcus*, *Peptoniphilus*, and *Peptostreptococcus* spp. (CLSI M100 Ed. 29, 2019).

5.2. Pharmacokinetic Properties

• Distribution

Both piperacillin and tazobactam are approximately 30% bound to plasma proteins. The protein binding of either piperacillin or tazobactam is unaffected by the presence of the other compound. Protein binding of the tazobactam metabolite is negligible.

Piperacillin/tazobactam is widely distributed in tissues and body fluids including intestinal mucosa, gallbladder, lung, bile, and bone. Mean tissue concentrations are generally 50% to 100% of those in plasma.

• Metabolism

Piperacillin is metabolized to a minor microbiologically active desethyl metabolite. Tazobactam is metabolized to a single metabolite that has been found to be microbiologically inactive.

• Elimination

Piperacillin and tazobactam are eliminated via the kidney by glomerular filtration and tubular secretion.

Piperacillin is excreted rapidly as unchanged drug with 68% of the administered dose appearing in the urine. Tazobactam and its metabolite are eliminated primarily by renal excretion with 80% of the administered dose appearing as unchanged drug and the remainder as the single metabolite. Piperacillin, tazobactam, and desethyl piperacillin are also secreted into the bile.

Following administration of single or multiple doses of piperacillin/tazobactam to healthy subjects, the plasma half-life of piperacillin and tazobactam ranged from 0.7 to 1.2 hours and was unaffected by dose or duration of infusion. The elimination half-lives of both piperacillin and tazobactam are increased with decreasing renal clearance.

There are no significant changes in the pharmacokinetics of piperacillin due to tazobactam. Piperacillin appears to reduce the rate of elimination of tazobactam.

- **Special Populations**

The half-lives of piperacillin and of tazobactam increase by approximately 25% and 18%, respectively, in patients with hepatic cirrhosis compared to healthy subjects.

The half-lives of piperacillin and tazobactam increase with decreasing creatinine clearance. The increase in half-life is two-fold and four-fold for piperacillin and tazobactam, respectively, at creatinine clearance below 20 mL/min compared to patients with normal renal function.

Hemodialysis removes 30% to 50% of piperacillin/tazobactam with an additional 5% of the tazobactam dose removed as the tazobactam metabolite. Peritoneal dialysis removes approximately 6% and 21% of the piperacillin and tazobactam doses, respectively, with up to 18% of the tazobactam dose removed as the tazobactam metabolite.

5.3. Preclinical Safety Data

- **Carcinogenicity**

Carcinogenicity studies have not been conducted with piperacillin, tazobactam, or the combination.

- **Mutagenicity**

Piperacillin/tazobactam was negative in microbial mutagenicity assays. Piperacillin/tazobactam was negative in the unscheduled DNA synthesis (UDS) test. Piperacillin/tazobactam was negative in a mammalian point mutation (Chinese hamster ovary cell hypoxanthine phosphoribosyltransferase [HPRT]) assay.

Piperacillin/tazobactam was negative in a mammalian cell (BALB/c-3T3) transformation assay. *In vivo*, piperacillin/tazobactam did not induce chromosomal aberrations in rats dosed intravenously.

Piperacillin was negative in microbial mutagenicity assays. There was no DNA damage in bacteria (Rec assay) exposed to piperacillin. Piperacillin was negative in the UDS test. In a mammalian point mutation (mouse lymphoma cells) assay, piperacillin was positive. Piperacillin was negative in a cell (BALB/c-3T3) transformation assay. *In vivo*, piperacillin did not induce chromosomal aberrations in mice dosed intravenously.

Tazobactam was negative in microbial mutagenicity assays. Tazobactam was negative in the UDS test. Tazobactam was negative in a mammalian point mutation (Chinese hamster ovary cell HPRT) assay. In another mammalian point mutation (mouse lymphoma cells) assay, tazobactam was positive. Tazobactam was negative in a cell (BALB/c-3T3) transformation assay. In an *in vitro* cytogenetics (Chinese hamster lung cells) assay, tazobactam was negative. *In vivo*, tazobactam did not induce chromosomal aberrations in rats dosed intravenously.

- **Reproductive Toxicity**

In embryo-fetal development studies, there was no evidence of teratogenicity following intravenous administration of tazobactam or the piperacillin/tazobactam combination; however, in rats there were slight reductions in fetal body weight at maternally toxic doses.

Intraperitoneal administration of piperacillin/tazobactam was associated with slight reductions in litter size and an increased incidence of minor skeletal anomalies (delays in bone ossification) at doses that produced maternal toxicity. Peri-/post-natal development was impaired (reduced pup weights, increase in still birth, increase in pup mortality), concurrent with maternal toxicity.

- **Impairment of Fertility**

Reproduction studies in rats revealed no evidence of impaired fertility due to tazobactam or piperacillin/tazobactam when administered intraperitoneally.

6. PHARMACEUTICAL PARTICULARS

6.1. Shelf-Life

Please see label and box for the expiration date.

6.2. Storage Condition

2 g/250 mg: Store at temperatures not exceeding 25°C.

4 g/500 mg: Store at temperatures not exceeding 30°C.

6.3. Availability

Piperacillin sodium/Tazobactam sodium (Tazocin) is available in 2 g/250 mg and 4 g/500 mg Vial.

6.4. Incompatibilities

Solutions known to be compatible with piperacillin/tazobactam containing EDTA for reconstitution are:

- 0.9% Sodium chloride for injection
- Sterile water for injection
- Dextrose 5%
- Bacteriostatic saline/parabens
- Bacteriostatic water/parabens
- Bacteriostatic saline/benzyl alcohol
- Bacteriostatic water/benzyl alcohol

The reconstituted solution of piperacillin/tazobactam containing EDTA may be further diluted to the desired volume (e.g., 50 mL to 150 mL) with one of the compatible solvents for intravenous use listed below:

- 0.9% Sodium chloride for injection
- Sterile water for injection[†]
- Dextrose 5%
- Dextran 6% in saline
- Lactated Ringer's Injection

- Hartmann's solution
- Ringer's acetate
- Ringer's acetate/malate

† Maximum recommended volume of sterile water for injection per dose is 50 mL.

Whenever piperacillin/tazobactam is used concurrently with another antibiotic (e.g., aminoglycosides), the drugs must be administered separately. The mixing of piperacillin/tazobactam with an aminoglycoside *in vitro* can result in substantial inactivation of the aminoglycoside.

The mixing of β -lactam antibiotics with aminoglycosides *in vitro* can result in substantial inactivation of the aminoglycoside. However, amikacin and gentamicin were determined to be compatible with piperacillin/tazobactam *in vitro* in certain diluents at specific concentrations (see **section 4.2 Dosage and Method of Administration**).

Piperacillin/tazobactam should not be mixed with other drugs in a syringe or infusion bottle since compatibility has not been established.

Because of chemical instability, piperacillin/tazobactam should not be used with solutions containing only sodium bicarbonate.

Piperacillin/tazobactam should not be added to blood products or albumin hydrolysates.

6.5. Special Precautions for Disposal and Other Handling

Directions for Reconstitution and Dilution for Use

Intravenous use only: Reconstitute each vial with the volume of solvent shown in the table below, using one of the compatible solvents for reconstitution. Swirl until dissolved.

When swirled constantly, reconstitution generally occurs within 5 to 10 minutes.

Vial Size (Piperacillin/tazobactam)	Volume of Compatible Solvent to be Added to Vial
2.25 g	10 mL
4.50 g	20 mL

7. FDA REGISTRATION NUMBER

2 g/250 mg: DR-XY39441

4 g/500 mg: DR-XY37731

8. DATE OF FIRST AUTHORIZATION/RENEWAL OF THE AUTHORIZATION

2 g/250 mg: 09 Aug 1999

4 g/500 mg: 09 Aug 1999

Keep out of reach of children.

For suspected adverse drug reaction, report to the FDA: www.fda.gov.ph

Seek medical attention immediately at the first sign of any adverse drug reaction.

CAUTION: Foods, Drugs, Devices and Cosmetics Act prohibits dispensing without prescription.

Manufactured by:

WYETH LEDERLE S.r.l.

Via Franco Gorgone Zona Industriale, Catania, Italy

Marketing Authorization Holder:

Pfizer, Inc.

18F – 20F 8 Rockwell Building
Hidalgo Drive, Rockwell Center
Makati City, Metro Manila
Philippines

Under Authority of PFIZER, INC., New York, N.Y., U.S.A.

Revision No.: 11.0

Revision Date: 08 October 2020

Reference: CDS version 30,31

Reference Date: 28 August 2019, 23 March 2020